Content Hub

Laura Pierce Interview Capture


CAR-TCR Conversation with...

Laura Pierce, Biomedical Engineer, NIST

In this conversation, Laura expresses her opinions on the greatest challenges currently facing developers of cell therapies, as well as her thoughts on what the future might hold for CAR-TCR.

Sarah Snykers Capture


CAR-TCR Conversation with...

Sarah Snykers, Quality Control Manager, Celyad

In this conversation, Sarah shares her thoughts on the best direction for cell therapy drug developers to take, in order to drive the progression of CAR-TCR treatments.

CART Industry Survey Snippet



CAR-TCR Industry Survey Results 2019

Here’s what your peers think about key developments and priorities in this rapidly evolving field.

Press Release: Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology


CAR-TCR Conversation with...

Peter Emtage, Senior Vice President, Head of Cell Therapy Research, Kite, a Gilead Company

In this conversation, Peter shares his views on the clinical and commercial progression of CAR-T therapies after a whirlwind few years.


CAR-TCR Conversation with...

David Sourdive, Executive Vice President, Technical Operations & Co-founder, Cellectis

In this conversation, David discusses the disruptive genetic engineering approaches developed to create efficacious, next generation CAR and TCR therapies.


CAR-TCR Industry Survey 2018

The infographic provides some great insights into solid tumor approaches, commercial impact and limitations of manufacturing strategies.